Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery

Stopped early · Phase 3

Conditions studied: Inflammation, Pain, Cataract

In brief

The objective of this study is to compare the safety and efficacy of Mapracorat Ophthalmic Suspension, 3% to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.

Key facts

Study ID

NCT01298752

Run by

Bausch & Lomb Incorporated

People needed

177

Starts

2011-02-01

Expected to finish

2011-11-01

Last updated by the study team

2020-09-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects who are candidates for routine, uncomplicated cataract surgery.
• Subjects must be willing to wait to undergo cataract surgery on the fellow eye until after the study has been completed.

You may not qualify if…

• Subjects who are expected to require treatment with any systemic or ocular (either eye) drugs specified in the protocol during the 18 days following cataract surgery or any systemic or ocular corticosteroids within 14 days prior to cataract surgery.
• Subjects who have known hypersensitivity or contraindication to the study drug(s) or their components.
• Subjects who have a severe/serious ocular condition or history/presence of chronic generalized systemic disease that the Investigator feels might increase the risk to the subject or confound the result(s) of the study.

Where it is running

• Bausch & Lomb Incorporated — Rochester, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.